EUPRAXIA PHARMACEUTICALS Business Summary

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company that generates value through the development and eventual commercialization of locally delivered, extended-release drug formulations. The company’s primary business segments are focused on musculoskeletal health and gastroenterology, leveraging its proprietary DiffuSphere™ technology—a polymer-based microsphere platform designed to provide targeted, long-lasting therapeutic activity with reduced systemic side effects. Its lead product candidates include EP-104IAR for osteoarthritis (OA) pain and EP-104GI for eosinophilic esophagitis (EoE), both of which aim to disrupt the standard of care by extending the duration of effect from days to months. Eupraxia operates in a competitive landscape alongside Pacira BioSciences, Heron Therapeutics, and Anika Therapeutics, positioning itself as a next-generation alternative with a superior safety profile and extended therapeutic window compared to existing corticosteroid suspensions. The company was co-founded by CEO Dr. James Helliwell, a former cardiothoracic anesthesiologist with expertise in clinical trial design, and Dr. Amanda Malone, who serves as Chief Operating and Scientific Officer and co-invented the DiffuSphere™ technology. The leadership team includes Chief Financial Officer Alex Rothwell, who returned to the role in February 2025 with over 25 years of investment banking experience, and Dr. Rahul Sarugaser, Executive Vice President of Corporate Development. Eupraxia’s strategic growth is overseen by a board of directors featuring industry veterans such as Richard Glickman and Joseph Freedman, and it recently secured $63.2 million in a public offering closed in February 2026. This capital infusion, supported by institutional investors like Bloom Burton & Co., provides a robust runway to advance its late-stage clinical programs and transition toward commercial-stage operations.